Goodwin-Led Biotech Pliant Therapeutics Files $86M IPO
Venture capital-backed Pliant Therapeutics Inc. on Monday filed an initial public offering estimated to raise $86 million to fund development of fibrosis treatments, guided by Goodwin Procter LLP and underwriter counsel...To view the full article, register now.
Already a subscriber? Click here to view full article